BIM在晚期非小细胞肺癌治疗中的作用

肺癌是全世界范围内发病率和死亡率最高的恶性肿瘤，其中非小细胞肺癌（non-small cell lung cancer，NSCLC）是肺癌中最常见的类型。随着对肺癌发病机制、生物学行为的深入研究及基因检测水平的提高，以表皮生长因子受体（epidermal growth fac? tor receptor，EGFR）和间变淋巴瘤激酶（anaplastic lymphoma kinase，ALK）为靶点药物的发现，在晚期NSCLC个体化治疗的发展中具有里程碑式的意义。BIM（Bcl-2 interaction mediator of cell death）是Bcl-2家族促凋亡蛋白中的一员，参与细胞凋亡的重要介质。近年来，有研究证实BIM的表达水平及多态性会影响晚期NSCLC靶向治疗及化疗的疗效。本文就BIM及其在晚期NSCLC靶向治疗及化疗中的作用进行综述。 

Effect of BIM on advanced non-small cell lung cancer

Lung cancer displays the highest morbidity and mortality worldwide. Non-small cell lung cancer (NSCLC) is the most com-mon type of lung cancer. In-depth research was performed on the pathogenesis and biological behavior of lung cancer and the im-provement of genetic testing level. The discovery of drugs targeting epidermal growth factor receptor and anaplastic lymphoma kinase plays a significant role in individual treatment of advanced NSCLC. BIM is a protein in the Bcl-2 family that promotes apoptosis, which leads to cell death. The BIM expression level and polymorphism can influence the therapeutic effect of targeted therapy and chemo-therapy on advanced NSCLC. Therefore, this review summarizes BIM and its effects on targeted therapy and chemotherapy for ad-vanced NSCLC.